Cargando…
Advances in the Progression and Prognosis Biomarkers of Chronic Kidney Disease
Chronic kidney disease (CKD) is one of the increasingly serious public health concerns worldwide; the global burden of CKD is increasingly due to high morbidity and mortality. At present, there are three key problems in the clinical treatment and management of CKD. First, the current diagnostic indi...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724575/ https://www.ncbi.nlm.nih.gov/pubmed/34992536 http://dx.doi.org/10.3389/fphar.2021.785375 |
_version_ | 1784625931921391616 |
---|---|
author | Yan, Zhonghong Wang, Guanran Shi, Xingyang |
author_facet | Yan, Zhonghong Wang, Guanran Shi, Xingyang |
author_sort | Yan, Zhonghong |
collection | PubMed |
description | Chronic kidney disease (CKD) is one of the increasingly serious public health concerns worldwide; the global burden of CKD is increasingly due to high morbidity and mortality. At present, there are three key problems in the clinical treatment and management of CKD. First, the current diagnostic indicators, such as proteinuria and serum creatinine, are greatly interfered by the physiological conditions of patients, and the changes in the indicator level are not synchronized with renal damage. Second, the established diagnosis of suspected CKD still depends on biopsy, which is not suitable for contraindication patients, is also traumatic, and is not sensitive to early progression. Finally, the prognosis of CKD is affected by many factors; hence, it is ineviatble to develop effective biomarkers to predict CKD prognosis and improve the prognosis through early intervention. Accurate progression monitoring and prognosis improvement of CKD are extremely significant for improving the clinical treatment and management of CKD and reducing the social burden. Therefore, biomarkers reported in recent years, which could play important roles in accurate progression monitoring and prognosis improvement of CKD, were concluded and highlighted in this review article that aims to provide a reference for both the construction of CKD precision therapy system and the pharmaceutical research and development. |
format | Online Article Text |
id | pubmed-8724575 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87245752022-01-05 Advances in the Progression and Prognosis Biomarkers of Chronic Kidney Disease Yan, Zhonghong Wang, Guanran Shi, Xingyang Front Pharmacol Pharmacology Chronic kidney disease (CKD) is one of the increasingly serious public health concerns worldwide; the global burden of CKD is increasingly due to high morbidity and mortality. At present, there are three key problems in the clinical treatment and management of CKD. First, the current diagnostic indicators, such as proteinuria and serum creatinine, are greatly interfered by the physiological conditions of patients, and the changes in the indicator level are not synchronized with renal damage. Second, the established diagnosis of suspected CKD still depends on biopsy, which is not suitable for contraindication patients, is also traumatic, and is not sensitive to early progression. Finally, the prognosis of CKD is affected by many factors; hence, it is ineviatble to develop effective biomarkers to predict CKD prognosis and improve the prognosis through early intervention. Accurate progression monitoring and prognosis improvement of CKD are extremely significant for improving the clinical treatment and management of CKD and reducing the social burden. Therefore, biomarkers reported in recent years, which could play important roles in accurate progression monitoring and prognosis improvement of CKD, were concluded and highlighted in this review article that aims to provide a reference for both the construction of CKD precision therapy system and the pharmaceutical research and development. Frontiers Media S.A. 2021-12-21 /pmc/articles/PMC8724575/ /pubmed/34992536 http://dx.doi.org/10.3389/fphar.2021.785375 Text en Copyright © 2021 Yan, Wang and Shi. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Yan, Zhonghong Wang, Guanran Shi, Xingyang Advances in the Progression and Prognosis Biomarkers of Chronic Kidney Disease |
title | Advances in the Progression and Prognosis Biomarkers of Chronic Kidney Disease |
title_full | Advances in the Progression and Prognosis Biomarkers of Chronic Kidney Disease |
title_fullStr | Advances in the Progression and Prognosis Biomarkers of Chronic Kidney Disease |
title_full_unstemmed | Advances in the Progression and Prognosis Biomarkers of Chronic Kidney Disease |
title_short | Advances in the Progression and Prognosis Biomarkers of Chronic Kidney Disease |
title_sort | advances in the progression and prognosis biomarkers of chronic kidney disease |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724575/ https://www.ncbi.nlm.nih.gov/pubmed/34992536 http://dx.doi.org/10.3389/fphar.2021.785375 |
work_keys_str_mv | AT yanzhonghong advancesintheprogressionandprognosisbiomarkersofchronickidneydisease AT wangguanran advancesintheprogressionandprognosisbiomarkersofchronickidneydisease AT shixingyang advancesintheprogressionandprognosisbiomarkersofchronickidneydisease |